The Oncologist, Vol. 12, No. 4, 426-437, April 2007; doi:10.1634/theoncologist.12-4-426
© 2007 AlphaMed Press
Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors
Dirk Strumberga,
Jeffrey W. Clarkb,
Ahmad Awadac,
Malcolm J. Moored,
Heike Richlya,
Alain Hendliszc,
Hal W. Hirtee,
Joseph P. Ederf,
Heinz-Josef Lenzg,
Brian Schwartzh
aDepartment of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Herne, Germany;
bMassachusetts General Hospital Cancer Center, Boston, Massachusetts, USA;
cJules Bordet Institute, Brussels, Belgium;
dPrincess Margaret Hospital, Toronto, Ontario, Canada;
eJuravinski Cancer Center, Hamilton, Ontario, Canada;
fDana-Farber Cancer Institute, Boston, Massachusetts, USA;
gUniversity of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA;
hBayer Pharmaceuticals Corporation, West Haven, Connecticut, USA
Key Words. Sorafenib • BAY 43-9006 • Phase I clinical trials • Review
Correspondence: Dirk Strumberg, M.D., Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Hölkeskampring 40, D-44621 Herne, Germany. Telephone: 49-2323-499-5252; Fax: 49-2323-499-1578; e-mail: dirk.strumberg{at}marienhospital-herne.de
Sorafenib is an oral multikinase inhibitor that inhibits Raf serine/threonine kinases and receptor tyrosine kinases involved in tumor growth and angiogenesis. It has demonstrated preclinical and clinical activity in several tumor types. Sorafenib 400 mg twice daily (bid) has been approved in several countries worldwide for the treatment of renal cell carcinoma. This review summarizes key safety, pharmacokinetic, and efficacy data from four phase I, single-agent, dose-escalation studies with sorafenib in patients with advanced refractory solid tumors (n = 173). These trials followed different treatment regimens (7 days on/7 days off, n = 19; 21 days on/7 days off, n = 44; 28 days on/7 days off, n = 41; or continuous dosing, n = 69) to establish the optimum dosing schedule. Sorafenib was generally well tolerated; most adverse events were mild to moderate in severity up to the defined maximum-tolerated dose of 400 mg twice daily (bid). The most frequently reported drug-related adverse events at any grade included fatigue (40%), anorexia (35%), diarrhea (34%), rash/desquamation (27%), and handfoot skin reaction (25%). Sorafenib demonstrated preliminary antitumor activity, particularly among patients with renal cell carcinoma or hepatocellular carcinoma: overall, two of 137 evaluable patients achieved partial responses and 38 (28%) had stable disease. Although there was high interpatient variability in plasma pharmacokinetics across these studies, this was not associated with an increased incidence or severity of toxicity. Preliminary studies suggest that phosphorylated extracellular signalrelated kinase in tumor cells or peripheral blood lymphocytes may be a useful biomarker for measuring and, ultimately, predicting the effects of sorafenib. Based on these findings, continuous daily 400 mg bid sorafenib was chosen as the optimal regimen for phase II/III studies. Trials are ongoing in renal cell carcinoma, hepatocellular carcinoma, melanoma, and non-small cell lung cancer.
Disclosure of potential conflicts of interest is found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
N. P. Shah, D.-W. Kim, H. Kantarjian, P. Rousselot, P. E. D. Llacer, A. Enrico, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, M. C. Muller, et al.
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
Haematologica,
February 1, 2010;
95(2):
232 - 240.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Guillet, T. Walter, J.-Y. Scoazec, T. Vial, C. Lombard-Bohas, and J. Dumortier
Sorafenib-Induced Bilateral Osteonecrosis of Femoral Heads
J. Clin. Oncol.,
January 10, 2010;
28(2):
e14 - e14.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Takezawa, I. Okamoto, K. Yonesaka, E. Hatashita, Y. Yamada, M. Fukuoka, and K. Nakagawa
Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells
Cancer Res.,
August 15, 2009;
69(16):
6515 - 6521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-Y. Liu, S.-H. Park, C. Morisseau, S. H. Hwang, B. D. Hammock, and R. H. Weiss
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo
Mol. Cancer Ther.,
August 1, 2009;
8(8):
2193 - 2203.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kim, F. M. Balis, and B. C. Widemann
Sorafenib and Sunitinib
Oncologist,
August 1, 2009;
14(8):
800 - 805.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. I. Sherman
Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers
J. Clin. Endocrinol. Metab.,
May 1, 2009;
94(5):
1493 - 1499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Escudier, C. Szczylik, T. E. Hutson, T. Demkow, M. Staehler, F. Rolland, S. Negrier, N. Laferriere, U. J. Scheuring, D. Cella, et al.
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol.,
March 10, 2009;
27(8):
1280 - 1289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Azad, J. B. Aragon-Ching, W. L. Dahut, M. Gutierrez, W. D. Figg, L. Jain, S. M. Steinberg, M. L. Turner, E. C. Kohn, and H. H. Kong
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Clin. Cancer Res.,
February 15, 2009;
15(4):
1411 - 1416.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Jilaveanu, C. Zito, S. J. Lee, K. L. Nathanson, R. L. Camp, D. L. Rimm, K. T. Flaherty, and H. M. Kluger
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Clin. Cancer Res.,
February 1, 2009;
15(3):
1076 - 1085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Houben, H. Voigt, C. Noelke, V. Hofmeister, J. C. Becker, and D. Schrama
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
Mol. Cancer Ther.,
February 1, 2009;
8(2):
433 - 440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Will, J. A. Dykens, S. Nadanaciva, B. Hirakawa, J. Jamieson, L. D. Marroquin, J. Hynes, S. Patyna, and B. A. Jessen
Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells
Toxicol. Sci.,
November 1, 2008;
106(1):
153 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Yang, T. E. Van Meter, R. Buettner, M. Hedvat, W. Liang, C. M. Kowolik, N. Mepani, J. Mirosevich, S. Nam, M. Y. Chen, et al.
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas
Mol. Cancer Ther.,
November 1, 2008;
7(11):
3519 - 3526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Dewaele, B. Wasag, J. Cools, R. Sciot, H. Prenen, P. Vandenberghe, A. Wozniak, P. Schoffski, P. Marynen, and M. Debiec-Rychter
Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation
Clin. Cancer Res.,
September 15, 2008;
14(18):
5749 - 5758.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Dal Lago, V. D'Hondt, and A. Awada
Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors
Oncologist,
August 1, 2008;
13(8):
845 - 858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. P. Shah, H. M. Kantarjian, D.-W. Kim, D. Rea, P. E. Dorlhiac-Llacer, J. H. Milone, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, A. Charbonnier, et al.
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
J. Clin. Oncol.,
July 1, 2008;
26(19):
3204 - 3212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Montagut, S. V. Sharma, T. Shioda, U. McDermott, M. Ulman, L. E. Ulkus, D. Dias-Santagata, H. Stubbs, D. Y. Lee, A. Singh, et al.
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Cancer Res.,
June 15, 2008;
68(12):
4853 - 4861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1110 - 1120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Moreno-Vinasco, M. Gomberg-Maitland, M. L. Maitland, A. A. Desai, P. A. Singleton, S. Sammani, L. Sam, Y. Liu, A. N. Husain, R. M. Lang, et al.
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension
Physiol Genomics,
April 1, 2008;
33(2):
278 - 291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Diago, J. S. Pulido, J. R. Molina, L. C. Collet, T. P. Link, and E. H. Ryan Jr
Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration
Mayo Clin. Proc.,
February 1, 2008;
83(2):
231 - 234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Costa and H. A. Drabkin
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Oncologist,
December 1, 2007;
12(12):
1404 - 1415.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by AlphaMed Press.
|
|